NTx, a Rio Rancho-based bioinformatics and biomanufacturing company, announced Tuesday that received a grant from the Bill & Melinda Gates Foundation to to help improve global access to mRNA vaccines and therapeutics, according to a press release.
The grant is designed to advance novel solutions for mRNA production and related supply chain challenges. Constrained capacity and relatively high production costs have limited patient access to COVID-19 vaccines, particularly in low- and middle-income countries, per the release.
“NTx is committed to improving global health and providing equitable access to vaccines and therapeutics. This grant will enable NTx to develop several process concepts that address critical bottlenecks in mRNA product supply and integrate these solutions into its proprietary, cell-free biomanufacturing platform,” Dr. Alex Koglin, co-founder and CEO of NTx, said in the release.
To learn more about NTx and its proprietary platform, visit ntxbio.com.